Copyright
©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Transplantation. Sep 10, 2018; 8(5): 150-155
Published online Sep 10, 2018. doi: 10.5500/wjt.v8.i5.150
Published online Sep 10, 2018. doi: 10.5500/wjt.v8.i5.150
Introduction of everolimus in kidney transplant recipients at a late posttransplant stage
Junji Uchida, Tomoaki Iwai, Tatsuya Nakatani, Department of Urology, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan
Author contributions: Uchida J, Iwai T and Nakatani T contributed equally to this work, generated the tables and wrote the manuscript.
Conflict-of-interest statement: We have no personal or financial interests to declare, and we have no financial support from an industry source for the current manuscript.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Junji Uchida, MD, PhD, Associate Professor, Department of Urology, Osaka City University Graduate School of Medicine, 1-4-3, Abeno-ku, Asahi-machi, Osaka 545-8585, Japan. m9492120@msic.med.osaka-cu.ac.jp
Telephone: +81-6-66453857 Fax: +81-6-66474426
Received: May 21, 2018
Peer-review started: May 21, 2018
First decision: June 6, 2018
Revised: June 23, 2018
Accepted: June 27, 2018
Article in press: June 28, 2018
Published online: September 10, 2018
Peer-review started: May 21, 2018
First decision: June 6, 2018
Revised: June 23, 2018
Accepted: June 27, 2018
Article in press: June 28, 2018
Published online: September 10, 2018
Core Tip
Core tip: Current immunosuppressive protocols consisting of calcineurin inhibitors (CNIs) and mycophenolate mofetil have improved short-term graft survival. However, improvements in long-term graft survival are restricted by nephrotoxicity associated with CNI. Everolimus is an exceedingly useful immunosuppressant for kidney transplant recipients when administered in combination with low-dose CNIs or with elimination of CNIs. Here, we summarize the current knowledge about the introduction of everolimus with CNI elimination or minimization in kidney transplant recipients at late posttransplant stage.